ATE474850T1 - Analoga von peptiden der relaxin-superfamilie - Google Patents

Analoga von peptiden der relaxin-superfamilie

Info

Publication number
ATE474850T1
ATE474850T1 AT04737019T AT04737019T ATE474850T1 AT E474850 T1 ATE474850 T1 AT E474850T1 AT 04737019 T AT04737019 T AT 04737019T AT 04737019 T AT04737019 T AT 04737019T AT E474850 T1 ATE474850 T1 AT E474850T1
Authority
AT
Austria
Prior art keywords
analogues
peptides
relaxin superfamily
relaxin
methods
Prior art date
Application number
AT04737019T
Other languages
English (en)
Inventor
Borgo Mark Del
John Wade
Ross D Bathgate
Richard A Hughes
Original Assignee
Florey Howard Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florey Howard Inst filed Critical Florey Howard Inst
Application granted granted Critical
Publication of ATE474850T1 publication Critical patent/ATE474850T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
AT04737019T 2003-06-20 2004-06-18 Analoga von peptiden der relaxin-superfamilie ATE474850T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003903124A AU2003903124A0 (en) 2003-06-20 2003-06-20 Analogues of heteromeric proteins
PCT/AU2004/000798 WO2004113381A1 (en) 2003-06-20 2004-06-18 Relaxin superfamily peptide analogues

Publications (1)

Publication Number Publication Date
ATE474850T1 true ATE474850T1 (de) 2010-08-15

Family

ID=31954163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04737019T ATE474850T1 (de) 2003-06-20 2004-06-18 Analoga von peptiden der relaxin-superfamilie

Country Status (9)

Country Link
US (1) US20070004619A1 (de)
EP (1) EP1641824B1 (de)
JP (1) JP2007534613A (de)
AT (1) ATE474850T1 (de)
AU (1) AU2003903124A0 (de)
CA (1) CA2534748C (de)
DE (1) DE602004028246D1 (de)
NZ (1) NZ544216A (de)
WO (1) WO2004113381A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CA2563433C (en) * 2004-04-30 2010-07-13 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US7893197B2 (en) * 2004-08-25 2011-02-22 Janssen Pharmaceutica N.V. Relaxin-3 chimeric polypeptides and their preparation and use
US20060052304A1 (en) * 2004-09-02 2006-03-09 Bas Medical, Inc. Method for remodeling bone and related sutures
US8496446B2 (en) * 2005-08-29 2013-07-30 Carrier Corporation Compressor muffler
US20110072955A1 (en) 2005-10-06 2011-03-31 Turner William D System and method for pacing repetitive motion activities
EP2129359B1 (de) * 2007-01-30 2012-03-14 Janssen Pharmaceutica, N.V. Chimärer peptidantagonist für gpcr135 oder gpcr142
WO2009140433A1 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of promoting wound healing
GR1006759B (el) * 2008-12-22 2010-04-20 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras) Εξελιγμενη χημικη μεθοδος συνθεσης της ανθρωπινης ρηλαξινης
JP5973427B2 (ja) * 2010-06-23 2016-08-23 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン類似体
US8883722B2 (en) * 2010-06-23 2014-11-11 Novo Nordisk A/S Human insulin containing additional disulfide bonds
CN102985440B (zh) 2010-06-23 2016-10-26 诺沃-诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2972902T3 (es) * 2010-08-17 2024-06-17 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
AU2011301146B2 (en) * 2010-09-08 2016-01-21 Howard Florey Institute Of Experimental Physiology And Medicine Single chain relaxin polypeptides
JP2015502971A (ja) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス Ｎ末端修飾インスリン誘導体
CN103456765B (zh) 2013-09-10 2015-09-16 深圳市华星光电技术有限公司 有源式有机电致发光器件背板及其制作方法
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN114075276A (zh) * 2020-08-17 2022-02-22 成都奥达生物科技有限公司 一种长效松弛素2类似物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287820B1 (de) * 1982-08-12 1992-07-08 Howard Florey Institute Of Experimental Physiology And Medicine Analoge des humanen Relaxins
IL70414A (en) * 1982-12-13 1991-06-10 Florey Howard Inst Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
US5911997A (en) * 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
AUPR814401A0 (en) * 2001-10-08 2001-11-01 Howard Florey Institute Of Experimental Physiology And Medicine Human 3 relaxin

Also Published As

Publication number Publication date
US20070004619A1 (en) 2007-01-04
DE602004028246D1 (de) 2010-09-02
JP2007534613A (ja) 2007-11-29
CA2534748C (en) 2013-09-17
WO2004113381A1 (en) 2004-12-29
EP1641824B1 (de) 2010-07-21
AU2003903124A0 (en) 2003-07-10
NZ544216A (en) 2008-09-26
EP1641824A1 (de) 2006-04-05
EP1641824A4 (de) 2008-02-13
CA2534748A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
ATE474850T1 (de) Analoga von peptiden der relaxin-superfamilie
ATE549028T1 (de) Stabile analoga von glp-1
HRP20050024A2 (en) Pegylated t20 polypeptide
CY1105763T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
HRP20040354B1 (en) Novel cyclosporin analog microemulsion preconcentrates
CY1107556T1 (el) Συνθεσεις αναλογων g-csf και μεθοδοι
EA200602257A1 (ru) Стабилизированные жидкие препаративные формы интерферона
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
DE69938935D1 (de) Zyklische conotoxin-peptide
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
ATE316101T1 (de) Thrombinspaltbare faktor-x-analoga
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
ATE412745T1 (de) Antiangiogene peptide vom n-terminus von endostatin
DE60118359D1 (de) Humanische pellino-polypeptide
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
DE69434151D1 (de) Therapeutische inhaltsstoffe
ATE467421T1 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
DE60327925D1 (de) Verwendung von löslichem fgl2 als immunosuppressivum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties